Changes in speech and language are hallmark characteristics of Alzheimer’s disease. While these changes are core to clinical evaluation, we have historically lacked objective tools for measuring these changes in the context of clinical trials. During this webinar, we review advances in speech biomarker validation, using both short, focused speech tasks as well as leveraging passively collected speech from clinical interviews.

Speakers:

Bill Simpson, Head of Partnerships at Winterlight Labs (Moderator)

Jessica Robin, Director of Clinical Research at Winterlight Labs

Mike Detke, CMO at Lighthouse Pharma

Jennifer Sorinas Nerin, Data Scientist at Novartis Institute for Biomedical Research (NIBR)

Watch the full recording: